OptimizeRx (OPRX) Moves 5.4% Higher: Will This Strength Last?
JMP Securities Maintains OptimizeRx(OPRX.US) With Buy Rating, Maintains Target Price $16
JMP Securities analyst Constantine Davides maintains $OptimizeRx(OPRX.US)$ with a buy rating, and maintains the target price at $16.According to TipRanks data, the analyst has a success rate of 23.5%
OptimizeRx: A Strong Buy on Client Commitments and Growth Potential
Lake Street Maintains OptimizeRx(OPRX.US) With Buy Rating, Maintains Target Price $15
Lake Street analyst Eric Martinuzzi maintains $OptimizeRx(OPRX.US)$ with a buy rating, and maintains the target price at $15.According to TipRanks data, the analyst has a success rate of 40.9% and a
Express News | OptimizeRx Continues to Expand Its Strategic Relationship With a Top-Tier Pharma Client via a Multi-Brand, Multi-Solution Investment Commitment With Over $10M in-Year Total Value
OptimizeRx Launches Novel Brand Eligibility Technology, Enabling Dynamic Direct to Consumer Marketing for Healthcare Audiences
Down -12.46% in 4 Weeks, Here's Why OptimizeRx (OPRX) Looks Ripe for a Turnaround
RBC Capital Maintains Outperform on OptimizeRx, Lowers Price Target to $14
RBC Capital Maintains OptimizeRx(OPRX.US) With Buy Rating, Cuts Target Price to $14
RBC Capital analyst Sean Dodge maintains $OptimizeRx(OPRX.US)$ with a buy rating, and adjusts the target price from $17 to $14.According to TipRanks data, the analyst has a success rate of 41.4% and
Express News | OptimizeRx Corp : RBC Cuts Target Price to $14 From $17
OptimizeRx | 10-Q: Q2 2024 Earnings Report
OptimizeRx Price Target Cut to $11.00/Share From $15.00 by Barclays
OptimizeRx Is Maintained at Equal-Weight by Barclays
OptimizeRx Analyst Ratings
Barclays Sticks to Its Hold Rating for OptimizeRx (OPRX)
Earnings Release: Here's Why Analysts Cut Their OptimizeRx Corporation (NASDAQ:OPRX) Price Target To US$15.79
OptimizeRx Second Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
Earnings Call: OptimizeRx Reports Solid Growth, Misses Revenue Target
Stifel Nicolaus Reaffirms Their Buy Rating on OptimizeRx (OPRX)
OptimizeRx Maintains Buy Rating: Robust Sales Pipeline and Improved Operational Efficiency Signal Strong Future Growth